- Home
- REAL vs GHRS Comparison
REAL vs GHRS Comparison
Compare REAL & GHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | REAL | GHRS |
|---|---|---|
| Founded | 2011 | 2018 |
| Country | United States | Ireland |
| Employees | N/A | N/A |
| Industry | Other Specialty Stores | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 892.0M |
| IPO Year | 2019 | 2021 |
Fundamental Metrics
Financial Performance| Metric | REAL | GHRS |
|---|---|---|
| Price | $14.37 | $13.25 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 7 | 9 |
| Target Price | $14.21 | ★ $30.11 |
| AVG Volume (30 Days) | ★ 2.8M | 237.1K |
| Earning Date | 11-10-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $662,789,000.00 | N/A |
| Revenue This Year | $17.10 | N/A |
| Revenue Next Year | $10.96 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 14.30 | N/A |
| 52 Week Low | $4.61 | $6.72 |
| 52 Week High | $16.24 | $20.50 |
Technical Indicators
Market Signals| Indicator | REAL | GHRS |
|---|---|---|
| Relative Strength Index (RSI) | 58.60 | 41.50 |
| Support Level | $13.89 | $13.94 |
| Resistance Level | $14.58 | $15.00 |
| Average True Range (ATR) | 0.62 | 0.84 |
| MACD | -0.07 | -0.15 |
| Stochastic Oscillator | 66.95 | 3.99 |
Price Performance
Historical ComparisonAbout REAL The RealReal Inc.
The RealReal is the largest pure-play luxury resale platform in the US, generating $1.8 billion in 2024 gross merchandise volume and addressing a niche (personal luxury resale) that had previously been serviced by inefficient upscale boutiques and local pawn shops. The company generates revenue via consignment and first-party sales on its online marketplace, and through a small volume of direct sales. With a hands-on approach that actively sources inventory and authenticates every item on its platform, The RealReal is able to justify much higher take rates than peers, working out to roughly 36% of net merchandise value in 2024, which excludes returns, cancellations, and first-party sales.
About GHRS GH Research PLC
GH Research PLC is a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment for depression. Its initial focus is on developing novel and proprietary mebufotenin therapies for the treatment of patients with Treatment-Resistant Depression, or TRD. Its portfolio currently includes GH001, a proprietary inhalable mebufotenin product candidate, and GH002, a proprietary intravenous mebufotenin product candidate. The group has only a single segment: Research and Development.